Burchert, A <br/><br/>
Interferon alpha 2 maintenance therapy may enable high rates of treatment discontinuation in chronic myeloid leukemia.  [electronic resource] 

 -  Leukemia  Jun 2015 
 - 1331-5 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1476-5551 
<br/><br/><label>Standard No.: </label>10.1038/leu.2015.45  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antineoplastic Agents--therapeutic use<br/>Benzamides--therapeutic use<br/>Cohort Studies<br/>Drug Therapy, Combination<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Imatinib Mesylate<br/>Interferon alpha-2<br/>Interferon-alpha--therapeutic use<br/>Leukemia, Myelogenous, Chronic, BCR-ABL Positive--drug therapy<br/>Male<br/>Middle Aged<br/>Neoplasm Recurrence, Local--drug therapy<br/>Neoplasm Staging<br/>Piperazines--therapeutic use<br/>Prognosis<br/>Pyrimidines--therapeutic use<br/>Recombinant Proteins--therapeutic use<br/>Remission Induction<br/>Survival Rate<br/>Young Adult